![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessImpact of the 2008 economic crisis on the burden of hepatitis B and C diseases in Southern European countries
The economic crisis that began in 2008 has severely affected Southern (Greece, Italy, Portugal, Spain) Western European (SWE) countries of Western Europe (WE) and may have affected ongoing efforts to eliminate...
-
Article
Open AccessEpidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
Hepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5...
-
Article
Open AccessHCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
In HIV-1/HCV-coinfected patients, chronic HCV infection leads to an increased T-lymphocyte immune activation compared to HIV-monoinfected patients, thereby likely contributing to increase HIV-1 reservoir that ...
-
Article
Open AccessEpidemic history of hepatitis C virus genotypes and subtypes in Portugal
Any successful strategy to prevent and control HCV infection requires an understanding of the epidemic behaviour among the different genotypes. Here, we performed the first characterization of the epidemic his...
-
Article
Open AccessLow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside cli...
-
Article
Open AccessSpatial pattern of HIV-1 cases of vertical transmission in Madrid (Spain): impact of demographic and socioeconomic factors
-
Article
Open AccessImpact of highly active antiretroviral therapy (HAART) on clinical outcomes of vertically HIV-1 infected children